Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 3Completed 3

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 24Neoplasms 22Carcinoma, Merkel Cell 20Neoplasm Metastasis 18Carcinoma, Renal Cell 17Colorectal Neoplasms 16Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 9Melanoma 9Head and Neck Neoplasms 8Stomach Neoplasms 7Recurrence 6Carcinoma, Hepatocellular 6Ureteral Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Urethral Neoplasms 4Sarcoma 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Squamous Cell 4Uterine Cervical Neoplasms 3Turcot syndrome 3Skin Neoplasms 3

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Recurrence × avelumab × Clear all
NCT04562441 2025-01-10

NPC - AXEL Study : Axitinib-Avelumab

Chinese University of Hong Kong

Phase 2 Completed
13 enrolled

Recurrence

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT03941262 2023-11-13

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

NKGen Biotech, Inc.

Phase 1 Completed
27 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

EMD Serono

Phase 3 Completed
371 enrolled 18 charts
Gastrointestinal

Recurrence, Stomach Neoplasms

NCT02603419 2020-04-24

JAVELIN HODGKINS

Pfizer

Phase 1 Terminated
34 enrolled 43 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡